Patents by Inventor David J. Wustrow

David J. Wustrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazole pyrimidine compounds and uses thereof
    Patent number: 11918582
    Abstract: Disclosed herein are pyrazole pyrimidine compounds that modulate and/or inhibit hematopoietic progenitor kinase 1, as well as methods of making such compounds and therapeutic methods of using same.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: March 5, 2024
    Assignee: RAPT Therapeutics, Inc.
    Inventors: Cyril Bucher, Adrian Dukes, Blanca Gomez, Hannah Haley, Dennis Hu, Jeffrey J. Jackson, Michelle Yoo Min Ko, Paul Leger, Anqi Ma, Andrew A. Ng, Daniel Poon, Omar Robles, Anton Shakhmin, Grant Shibuya, Parcharee Tivitmahaisoon, Vi-Anh Vu, David J. Wustrow, Mikhail Zibinsky
  • ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG
    Publication number: 20240024249
    Abstract: Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.
    Type: Application
    Filed: June 13, 2023
    Publication date: January 25, 2024
    Inventors: Sarina Grace Harris MA, Laura Elizabeth BAUER, Sami KARABORNI, David J. WUSTROW, Peter A. VIRSIK
  • CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20230322741
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Application
    Filed: April 5, 2023
    Publication date: October 12, 2023
    Inventors: Parcharee Tivitmahaisoon, David J. Wustrow, Mikhail Zibinsky, Omar Robles
  • PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20220305018
    Abstract: Disclosed herein are pyrazole pyrimidine compounds that modulate and/or inhibit hematopoietic progenitor kinase 1, as well as methods of making such compounds and therapeutic methods of using same.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 29, 2022
    Inventors: Cyril Bucher, Adrian Dukes, Blanca Gomez, Hannah Haley, Dennis Hu, Jeffrey J. Jackson, Michelle Yoo Min Ko, Paul Leger, Anqi Ma, Andrew A. Ng, Daniel Poon, Omar Robles, Anton Shakhmin, Grant Shibuya, Parcharee Tivitmahaisoon, Vi-Anh Vu, David J. Wustrow, Mikhail Zibinsky
  • METHODS OF MAKING TRANS ISOMERIC FORMS OF G PROTEIN-COUPLED RECEPTOR MODULATORS
    Publication number: 20220251070
    Abstract: Disclosed herein, inter alia, methods of synthesis of trans isomeric forms of G protein-coupled receptor modulators of high trans isomeric purity.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 11, 2022
    Inventors: Cyril Bucher, James P. Davidson, Jeffrey J. Jackson, Michelle Yoo Min Ko, Grant Shibuya, David J. Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
    Patent number: 11046699
    Abstract: Disclosed herein are pyrozolo-pyrimidin-amino-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: June 29, 2021
    Assignee: RAPT THERAPEUTICS, INC.
    Inventors: Minna H. T. Bui, Adrian O. Dukes, Xinping Han, Dennis X. Hu, Jeffrey J. Jackson, Yoo Min Ko, Paul R. Leger, Anqi Ma, Jack Maung, Andrew A. Ng, Akinori Okano, Omar Robles, Grant Shibuya, Hunter P. Shunatona, Jacob B. Schwarz, Anton A. Shakhmin, David J. Wustrow, Mikhail Zibinsky
  • CRYSTALLINE FORMS OF C-C CHEMOKINE RECEPTOR TYPE 4 ANTAGONIST AND USES THEREOF
    Publication number: 20210139487
    Abstract: Crystalline forms of a C-C chemokine receptor type 4 (CCR4) antagonist, oral dosage forms of same and methods of using and preparing same, are provided.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 13, 2021
    Inventors: David J. ARNOLD, Omar ROBLES, Duane E. RUDISILL, David J. WUSTROW, Mikhail ZIBINSKY, Sami KARABORNI
  • Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
    Patent number: 10940117
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: March 9, 2021
    Assignee: Arbor Pharmaceuticals, LLC
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF
    Publication number: 20200246271
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Application
    Filed: April 20, 2020
    Publication date: August 6, 2020
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
    Patent number: 10716760
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 21, 2020
    Assignee: Arbor Pharmaceuticals, LLC
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE
    Publication number: 20200087272
    Abstract: Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.
    Type: Application
    Filed: April 29, 2019
    Publication date: March 19, 2020
    Applicant: Arbor Pharmaceuticals, LLC
    Inventors: Peter A. Virsik, David J. Wustrow, Thamil Annamalai, Suresh K. Manthati
  • PYRAZOLO-PYRIMIDIN-AMINO-CYCLOALKYL COMPOUNDS AND THEIR THERAPEUTIC USES
    Publication number: 20190375753
    Abstract: Disclosed herein are pyrozolo-pyrimidin-amino-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 12, 2019
    Inventors: Minna H. T. Bui, Adrian O. Dukes, Xinping Han, Dennis X. Hu, Jeffrey J. Jackson, Yoo Min Ko, Paul R. Leger, Anqi Ma, Jack Maung, Andrew A. Ng, Akinori Okano, Omar Robles, Grant Shibuya, Hunter P. Shunatona, Jacob B. Schwarz, Anton A. Shakhmin, David J. Wustrow, Mikhail Zibinsky
  • Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
    Publication number: 20190256481
    Abstract: Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Inventors: Peter A. Virsik, David J. Wustrow, Thamil Annamalai, Suresh K. Manthati
  • Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
    Publication number: 20190256480
    Abstract: Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Inventors: Peter A. Virsik, David J. Wustrow, Thamil Annamalai, Suresh K. Manthati
  • TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE
    Publication number: 20180273500
    Abstract: Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Applicant: XenoPort, Inc.
    Inventors: Peter A. Virsik, David J. Wustrow, Thamil Annamalai, Suresh K. Manthati
  • TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE
    Publication number: 20180237405
    Abstract: Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Applicant: XenoPort, Inc.
    Inventors: Peter A. Virsik, David J. Wustrow, Thamil Annamalai, Suresh K. Manthati
  • ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF
    Publication number: 20170157056
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Application
    Filed: January 7, 2016
    Publication date: June 8, 2017
    Applicant: XENOPORT, INC.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
    Patent number: 9597292
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: March 21, 2017
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF
    Publication number: 20160113879
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Application
    Filed: January 7, 2016
    Publication date: April 28, 2016
    Applicant: XENOPORT, INC.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • 5-membered heterocyclic amides and related compounds
    Patent number: 9133204
    Abstract: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: September 15, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Hongbin Li, Jun Yuan, Rajagopal Bakthavatchalam, Kevin J Hodgetts, Qin Guo, Scott M. Capitosti, Jianmin Mao, David J. Wustrow